A Phase 3 interventional study of ABI-007 and Dacarbazine in Malignant Melanoma, sponsored by Celgene. Completed at 112 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-30.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing Albumin-Bound Paclitaxel in Melanoma — none open to participants now, none under way, none of them phase 3. Albumin-Bound Paclitaxel · Melanoma.
Among the 16 studies testing Albumin-Bound Paclitaxel in Melanoma, this one has the largest enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2009, is the only one in phase 3, and was the 8th registered.
3,372 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →None of the 16 studies testing Albumin-Bound Paclitaxel in Melanoma is open now. The open studies under Melanoma, anywhere →
Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 1
First in 2003; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 529 is above the median of 40 across 2,651 interventional studies indexed under Melanoma.
Median enrollment 30 across the 15 interventional studies. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 16 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
111 studies in Melanoma by Bristol-Myers Squibb: 3 open now, 9 under way, 3 of them phase 3. Of 90 finished, 41 (46%) have results posted.
Among the 111 studies in Melanoma by Bristol-Myers Squibb, this one is the 17th largest by enrollment of the 75 interventional ones that give a count, is one of 4 that started in 2009, is one of 21 in phase 3, and was the 26th registered.
Bristol-Myers Squibb’s Melanoma studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing Albumin-Bound Paclitaxel in Melanoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 111 in Melanoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this research study is to compare the safety, tolerability, and anti tumor activity of an investigational drug, ABI-007 versus Dacarbazine in patients with metastatic melanoma who have not previously received chemotherapy. ABI-007 is a new preparation of the active drug paclitaxel. It contains the same medication as the prescription chemotherapy drug Abraxane®. Abraxane® is approved by the FDA for the treatment of metastatic breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Dacarbazine is approved by the FDA for the treatment of melanoma. In this study, ABI-007 and Dacarbazine will be tested as therapy for people who have not yet had any cancer treatment for the diagnosis of metastatic melanoma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment Arm A (ABI-007): Patients who receive ABI-007 will be dosed intravenously over approximately 30 minutes without steroid pre-medication and without G-CSF prophylaxis (unless modified as described below). ABI-007 150 mg/m2 will be administered on Days 1, 8, and 15 every 4 weeks.
Drug: ABI-007
Treatment Arm B (dacarbazine): Patients who receive dacarbazine will be dosed intravenously at 1000 mg/m2 on Day 1 with steroid and antiemetic pre-medication. Treatment will be repeated every 21 days.
Drug: Dacarbazine
Patients who receive ABI-007 will be dosed intravenously over approximately 30 minutes without steroid pre-medication and without G-CSF prophylaxis (unless modified as described below). ABI-007 150 mg/m2 will be administered on Days 1, 8, and 15 every 4 weeks.
Also known as: Abraxane
Patients who receive dacarbazine will be dosed intravenously at 1000 mg/m2 on Day 1 with steroid and antiemetic pre-medication. Treatment will be repeated every 21 days.
Also known as: Dtic-Dome, DTIC-Dome
Progression Free Survival (PFS) Based on a Blinded Radiology Assessment of Response Using Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines
PFS was defined as the time from the randomization date to the start of disease progression or patient death, whichever occurred first. Participants who did not have disease progression or had not died were censored at the last known time that the patient was progression free. In the event of palliative radiotherapy or surgery, they were censored at the last assessment where they were documented to be progression-free prior to the date of radiotherapy or surgery. In follow up, participants who began new anticancer therapy prior to documented progression were censored at the last assessment where they were documented as progression free. Those with two or more missing response assessments prior to a visit with documented disease progression (or death) were censored at the last visit where they were documented to be progression free. RECIST defines progressive disease as a ≥ 20% increase taking as reference the smallest sum of the longest diameters recorded since the treatment began.
Time frame: Response assessment completed every 8 weeks until disease progression for up to 106 weeks; data cut off 30 June 2012
Participant Survival
Survival was defined as the time from the date of randomization to the date of death (any cause). Participants were censored at the last known time that they were alive.
Time frame: Up to 38 months; Up to data cut off of 30 June 2012
Summary of Treatment-emergent Adverse Events (AEs)
A Treatment Emergent AE (TEAE) was any AE that began or worsened after the start of the study drug through 30 days after the last dose of study drug or end of study whichever is later. A treatment related toxicity was one considered by the investigator to be possibly, probably or definitely related to study drug. AE's were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) V 3.0 criteria and the following scale: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life threatening, and Grade 5 = Death A SAE is any untoward medical occurrence at any dose that is fatal or life threatening, results in persistent or significant disability or incapacity; requires prolonged hospitalizations; is a congenital anomaly birth defect in the offspring of a patient, and conditions not included in the above that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above.
Time frame: Maximum exposure to study drug was 106 weeks; up to data cut off of 30 June 2012
Number of Participants Experiencing Dose Reductions, or Dose Interruptions, or Dose Delays of Study Drug
The number of participants with dose reductions, dose interruptions and dose delays that occurred during the treatment period. Dose reductions, interruptions and delays are typically caused by clinically significant laboratory abnormalities and /or treatment emergent adverse events/toxicities.
Time frame: Maximum study drug exposure 106 weeks; data cut off 30 June 2012
Nadir for the Absolute Neutrophil Count (ANC) Measurements
Maximal degree of myelosuppression during study drug dosing was represented by the nadir in ANC measurements over all treatment cycles.
Time frame: Day 1 up to 106 weeks; up to data cut off 30 June 2012
Nadir for White Blood Cells (WBCs) Measurements
Maximal degree of myelosuppression was represented by the nadir in white blood cells (WBCs) count measurements over all treatment cycles.
Time frame: Day 1 up to 106 weeks; up to data cut off 30 June 2012
Nadir for Platelet Count Measurements.
Maximal degree of myelosuppression was represented by the nadir in platelet count measurements over all treatment cycles.
Time frame: Day 1 up to 106 weeks; up to data cut off 30 June 2012
Nadir for the Hemoglobin Count Measurements
Maximal degree of myelosuppression during study drug dosing was represented by the nadir in hemoglobin count measurements over all treatment cycles.
Time frame: Day 1 up to 106 weeks; up to data cut off 30 June 2012
Pharmacokinetic Parameters
Time frame: On Cycle 1, Day 1 blood samples were taken at 0.25, 3.5, and 24 hr post-infusion end of the initial dose
Progression-free Survival (PFS) Based on Investigator Assessment Using RECIST Response Guidelines
PFS was defined as the time from the randomization date to the start of disease progression or patient death, whichever occurred first. Participants who did not have disease progression or had not died were censored at the last known time that the patient was progression free. In the event of palliative radiotherapy or surgery, they were censored at the last assessment where they were documented to be progression-free prior to the date of radiotherapy or surgery. In follow up, patients who began new anticancer therapy prior to documented progression were censored at the last assessment where they were documented as progression free. Those with two or more missing response assessments prior to a visit with documented disease progression (or death) were censored at the last visit where they were documented to be progression free.
Time frame: Response assessments completed every 8 weeks until disease progression; up to data cut off 30 June 2012; 38 months
Percent of Participants Who Achieve an Objective Confirmed Complete or Partial Response Based on Blinded Radiology Assessment of Response by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0
RECIST defines complete response (CR): The disappearance of all known disease and no new sites or disease related symptoms confirmed at least 4 weeks after initial documentation. All sites must be assessed, including non-measurable sites, such as effusions, or markers. Disappearance of all non-target lesions. The normalization of tumor marker level confirmed at least 4 weeks after initial documentation. Partial response (PR): At least a 30% decrease in the sum of the longest diameters of target lesions, taking as a reference the baseline sum of the longest diameters confirmed at least 4 weeks after initial documentation. PR is also recorded when all measurable disease has completely disappeared, but a non-measurable component (i.e., ascites) is still present but not progressing. As well as persistence of one or more non-target lesion(s) and/or the maintenance of tumor marker level above the normal limits.
Time frame: every 8 weeks; up to data cut off 30 June 2012
Percent of Participants With Stable Disease (SD) for ≥ 16 Weeks, or Confirmed Complete or Partial Response (i.e., Disease Control) Based on a Blinded Radiology Assessment of Response
Disease control is stable disease (SD) for \>=16 weeks + complete response (CR) + partial response (PR). See Outcome #4 for definitions of CR and PR. RECIST defines SD for target lesions as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, no occurrence of progression disease for non-target lesions, and no new lesions.
Time frame: Response assessment completed every 8 weeks until disease progression; up to data cut-off 30 June 2012
Duration of Response (DOR) in Responding Participants
Duration of response (DOR) as measured by PFS based on radiological review for participants who achieved an objective confirmed response of CR or PR. DOR was defined as progression-free survival in responders, i.e. as the time between the start of a complete response (CR) or partial response (PR) and the start of progressive disease (PD) or participants death from any cause, whichever occurred first. Participants that did not have progression or had not died were censored at the last known time the participant was progression free. Participants that had initiated other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Complete response (CR) and partial response (PR) are defined in outcome #4. Progressive disease was defined as at least a 20% increase in the sum of the longest diameters of target lesions; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.
Time frame: up to data cut off 30 June 2012
This multicenter study was conducted by investigators in 9 countries: Australia, Canada, France, Germany, Italy, Netherlands, Spain, United Kingdom and the United States (US) and treatment was given on an outpatient basis. First participant enrolled 30 April 2011, last participant enrolled June 2011..
| Milestone | ABI-007 150mg/m^2 | Dacarbazine 1000mg/m^2 |
|---|---|---|
| Started | 264 | 265 |
| Treated | 257 | 258 |
| Completed | 165 | 207 |
| Not completed | 99 | 58 |
| Withdrew: Adverse event | 56 | 11 |
| Withdrew: Unrelated adverse event | 3 | 1 |
| Withdrew: Physician decision | 11 | 15 |
| Withdrew: Protocol violation | 0 | 2 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Withdrawal by subject | 18 | 18 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Ongoing | 2 | 3 |
| Withdrew: Untreated | 7 | 7 |
PFS was defined as the time from the randomization date to the start of disease progression or patient death, whichever occurred first. Participants who did not have disease progression or had not died were censored at the last known time that the patient was progression free. In the event of palliative radiotherapy or surgery, they were censored at the last assessment where they were documented to be progression-free prior to the date of radiotherapy or surgery. In follow up, participants who began new anticancer therapy prior to documented progression were censored at the last assessment where they were documented as progression free. Those with two or more missing response assessments prior to a visit with documented disease progression (or death) were censored at the last visit where they were documented to be progression free. RECIST defines progressive disease as a ≥ 20% increase taking as reference the smallest sum of the longest diameters recorded since the treatment began.
| months | ABI-007 150mg/m^2 | Dacarbazine 1000mg/m^2 |
|---|---|---|
| Progression Free Survival (PFS) Based on a Blinded Radiology Assessment of Response Using Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines | 4.8 (3.7 to 5.5) | 2.5 (2.0 to 3.6) |
Survival was defined as the time from the date of randomization to the date of death (any cause). Participants were censored at the last known time that they were alive.
| months | ABI-007 150mg/m^2 | Dacarbazine 1000mg/m^2 |
|---|---|---|
| Participant Survival | 12.8 (11.3 to 14.6) | 10.7 (9.6 to 12.5) |
PFS was defined as the time from the randomization date to the start of disease progression or patient death, whichever occurred first. Participants who did not have disease progression or had not died were censored at the last known time that the patient was progression free. In the event of palliative radiotherapy or surgery, they were censored at the last assessment where they were documented to be progression-free prior to the date of radiotherapy or surgery. In follow up, patients who began new anticancer therapy prior to documented progression were censored at the last assessment where they were documented as progression free. Those with two or more missing response assessments prior to a visit with documented disease progression (or death) were censored at the last visit where they were documented to be progression free.
| months | ABI-007 150mg/m^2 | Dacarbazine 1000mg/m^2 |
|---|---|---|
| Progression-free Survival (PFS) Based on Investigator Assessment Using RECIST Response Guidelines | 3.7 (3.1 to 3.9) | 2.1 (1.9 to 2.5) |
RECIST defines complete response (CR): The disappearance of all known disease and no new sites or disease related symptoms confirmed at least 4 weeks after initial documentation. All sites must be assessed, including non-measurable sites, such as effusions, or markers. Disappearance of all non-target lesions. The normalization of tumor marker level confirmed at least 4 weeks after initial documentation. Partial response (PR): At least a 30% decrease in the sum of the longest diameters of target lesions, taking as a reference the baseline sum of the longest diameters confirmed at least 4 weeks after initial documentation. PR is also recorded when all measurable disease has completely disappeared, but a non-measurable component (i.e., ascites) is still present but not progressing. As well as persistence of one or more non-target lesion(s) and/or the maintenance of tumor marker level above the normal limits.
| percentage of participants | ABI-007 150mg/m^2 | Dacarbazine 1000mg/m^2 |
|---|---|---|
| Complete Response (CR) | 0 | 0 |
| Partial Response (PR) | 15 | 11 |
Disease control is stable disease (SD) for \>=16 weeks + complete response (CR) + partial response (PR). See Outcome #4 for definitions of CR and PR. RECIST defines SD for target lesions as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, no occurrence of progression disease for non-target lesions, and no new lesions.
| percent of participants | ABI-007 150mg/m^2 | Dacarbazine 1000mg/m^2 |
|---|---|---|
| Percent of Participants With Stable Disease (SD) for ≥ 16 Weeks, or Confirmed Complete or Partial Response (i.e., Disease Control) Based on a Blinded Radiology Assessment of Response | 39 | 27 |
Duration of response (DOR) as measured by PFS based on radiological review for participants who achieved an objective confirmed response of CR or PR. DOR was defined as progression-free survival in responders, i.e. as the time between the start of a complete response (CR) or partial response (PR) and the start of progressive disease (PD) or participants death from any cause, whichever occurred first. Participants that did not have progression or had not died were censored at the last known time the participant was progression free. Participants that had initiated other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Complete response (CR) and partial response (PR) are defined in outcome #4. Progressive disease was defined as at least a 20% increase in the sum of the longest diameters of target lesions; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.
| months | ABI-007 150mg/m^2 | Dacarbazine 1000mg/m^2 |
|---|---|---|
| Duration of Response (DOR) in Responding Participants | 11.1 (7.3 to NA) | 16.4 (11.0 to 21.8) |
A Treatment Emergent AE (TEAE) was any AE that began or worsened after the start of the study drug through 30 days after the last dose of study drug or end of study whichever is later. A treatment related toxicity was one considered by the investigator to be possibly, probably or definitely related to study drug. AE's were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) V 3.0 criteria and the following scale: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life threatening, and Grade 5 = Death A SAE is any untoward medical occurrence at any dose that is fatal or life threatening, results in persistent or significant disability or incapacity; requires prolonged hospitalizations; is a congenital anomaly birth defect in the offspring of a patient, and conditions not included in the above that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above.
| participants | ABI-007 150mg/m^2 | Dacarbazine 1000mg/m^2 |
|---|---|---|
| ≥1 TEAE | 255 | 239 |
| ≥1 TEAE related to study drug | 250 | 212 |
| ≥1 NCI CTCAE Grade (GR) 3 or above | 167 | 117 |
| ≥1 NCI CTCAE GR 3 or above TEAE to study drug | 129 | 71 |
| ≥1 TEAE with outcome of death | 8 | 1 |
| ≥1 drug related TEAE with outcome of death | 2 | 1 |
| ≥1 serious TEAE | 62 | 54 |
| ≥1 serious TEAE related to study drug | 23 | 17 |
| ≥1 TEAE leading to a dose reduction of study drug | 81 | 51 |
| ≥1 related TEAE leading to dose reduction | 80 | 49 |
| ≥1 TEAE leading to drug interruption | 4 | 16 |
| ≥1 drug related TEAE leading to drug interruption | 3 | 15 |
| ≥1 TEAE leading to dose delay of study drug | 124 | 84 |
| ≥1 drug related TEAE leading to dose delay | 106 | 77 |
| ≥1 TEAE leading to drug discontinuation | 59 | 12 |
| ≥1 drug related TEAE leading to drug discontinuing | 56 | 11 |
The number of participants with dose reductions, dose interruptions and dose delays that occurred during the treatment period. Dose reductions, interruptions and delays are typically caused by clinically significant laboratory abnormalities and /or treatment emergent adverse events/toxicities.
| participants | ABI-007 150mg/m^2 | Dacarbazine 1000mg/m^2 |
|---|---|---|
| Dose Reductions | 81 | 51 |
| Dose Interruptions | 6 | 17 |
| Dose Delay | 145 | 105 |
Maximal degree of myelosuppression during study drug dosing was represented by the nadir in ANC measurements over all treatment cycles.
| 10^9/L | ABI-007 150mg/m^2 | Dacarbazine 1000mg/m^2 |
|---|---|---|
| Nadir for the Absolute Neutrophil Count (ANC) Measurements | 1.50 ± 1.591 | 2.40 ± 1.694 |
Maximal degree of myelosuppression was represented by the nadir in white blood cells (WBCs) count measurements over all treatment cycles.
| 10^9/L | ABI-007 150mg/m^2 | Dacarbazine 1000mg/m^2 |
|---|---|---|
| Nadir for White Blood Cells (WBCs) Measurements | 3.00 ± 1.934 | 4.10 ± 1.968 |
Maximal degree of myelosuppression was represented by the nadir in platelet count measurements over all treatment cycles.
| 10^9/L | ABI-007 150mg/m^2 | Dacarbazine Arm B |
|---|---|---|
| Nadir for Platelet Count Measurements. | 228.5 ± 71.40 | 153 ± 92.01 |
Maximal degree of myelosuppression during study drug dosing was represented by the nadir in hemoglobin count measurements over all treatment cycles.
| g/L | ABI-007 150mg/m^2 | Dacarbazine 1000mg/m^2 |
|---|---|---|
| Nadir for the Hemoglobin Count Measurements | 109.0 (65.0 to 137) | 122.0 (65 to 161) |
No measurements were reported for this outcome.
Collected over Any adverse event (AE) that started at any time from the time the signing of the informed consent to 30 days after the last dose of study drug or End of Study was followed and reported; maximum drug exposure 106 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ABI-007 Arm A | — | 62/257 (24.1%) | 253/257 (98.4%) |
| Dacarbazine Arm B | — | 54/258 (20.9%) | 232/258 (89.9%) |
| Event | ABI-007 Arm A | Dacarbazine Arm B |
|---|---|---|
| PyrexiaGeneral disorders | 2/257 | 5/258 |
| PneumoniaInfections and infestations | 4/257 | 1/258 |
| CellulitisInfections and infestations | 3/257 | 4/258 |
| ErysipelasInfections and infestations | 3/257 | 0/258 |
| Urinary tract infectionInfections and infestations | 3/257 | 0/258 |
| Small intestinal obstructionGastrointestinal disorders | 3/257 | 1/258 |
| Febrile neutropeniaBlood and lymphatic system disorders | 3/257 | 1/258 |
| Peripheral motor neuropathyNervous system disorders | 2/257 | 0/258 |
| Peripheral sensory neuropathyNervous system disorders | 2/257 | 0/258 |
| VomitingGastrointestinal disorders | 2/257 | 2/258 |
| Event | ABI-007 Arm A | Dacarbazine Arm B |
|---|---|---|
| AlopeciaSkin and subcutaneous tissue disorders | 177/257 | 9/258 |
| FatigueGeneral disorders | 134/257 | 110/258 |
| NauseaGastrointestinal disorders | 104/257 | 130/258 |
| DiarrhoeaGastrointestinal disorders | 103/257 | 45/258 |
| Neuropathy peripheralNervous system disorders | 98/257 | 6/258 |
| ConstipationGastrointestinal disorders | 83/257 | 89/258 |
| RashSkin and subcutaneous tissue disorders | 72/257 | 18/258 |
| Decreased appetiteMetabolism and nutrition disorders | 68/257 | 52/258 |
| NeutropeniaBlood and lymphatic system disorders | 66/257 | 63/258 |
| DysgeusiaNervous system disorders | 62/257 | 24/258 |
Intent-to-Treat (ITT) Population: The ITT population consisted of all randomized participants regardless of whether the participant received any study drug or had any efficacy assessments collected.
| Age, Continuous(years) | ABI-007 150mg/m^2 | Dacarbazine Arm B 1000mg/m^2 | Total |
|---|---|---|---|
| Median | 62.0 ± 13.44 | 64.0 ± 12.06 | 63.0 ± 12.85 |
| Sex: Female, Male(Participants) | ABI-007 150mg/m^2 | Dacarbazine Arm B 1000mg/m^2 | Total |
|---|---|---|---|
| Female | 91 | 91 | 182 |
| Male | 173 | 174 | 347 |
| Eastern Cooperative Oncology Group Performance Status(participants) | ABI-007 150mg/m^2 | Dacarbazine Arm B 1000mg/m^2 | Total |
|---|---|---|---|
| 0 = Fully Active | 195 | 181 | 376 |
| 1= Restrictive but Ambulatory | 68 | 82 | 150 |
| 2 = Ambulatory but Unable to Work | 1 | 2 | 3 |
| 3 = Limited Self-Care | 0 | 0 | 0 |
| 4 = Completely Disabled | 0 | 0 | 0 |
| Baseline Lactate Dehydrogenase value(participants) | ABI-007 150mg/m^2 | Dacarbazine Arm B 1000mg/m^2 | Total |
|---|---|---|---|
| <0.8 * Upper Limit of Normal (ULN) | 138 | 139 | 277 |
| 0.8-1.1 * ULN | 72 | 69 | 141 |
| >1.1-2 * ULN | 51 | 56 | 107 |
| >2 * ULN | 3 | 1 | 4 |
| Metastatic Stage(participants) | ABI-007 150mg/m^2 | Dacarbazine Arm B 1000mg/m^2 | Total |
|---|---|---|---|
| M1a | 27 | 21 | 48 |
| M1b | 66 | 69 | 135 |
| M1c | 171 | 175 | 346 |
| BRAF Status(participants) | ABI-007 150mg/m^2 | Dacarbazine Arm B 1000mg/m^2 | Total |
|---|---|---|---|
| V 600 E | 65 | 67 | 132 |
| Wild Type (mutation negative) | 116 | 108 | 224 |
| unknown | 83 | 90 | 173 |
Showing the first 100 of 112 sites across 9 countries. Choose a country and city above to see the rest.
Ran from Apr 2009 to primary completion in Jun 2012, 37 months.
Results were first posted in Jun 2014, 2 years after primary completion. A results delay was requested in Aug 2013.
Of 64 industry-sponsored phase 3 interventional studies under Melanoma, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 49. This study's 37 months is close to that.
Counting every sponsor, half of 95 studies reached it within 47 months; a quarter within 30 and three quarters within 94.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Albumin-Bound Paclitaxel